Kolon Life Science to Export $207 Million of Gene Therapy Treatment to China’s Hainan Province

Published on: July 20, 2018
Author: Amy Liu

South Korea’s Kolon Life Science signed a $207 million contract to export its osteoarthritis drug, Invossa-K, to China Life Medical Centre in Hainan Province. Invossa-K, the world’s first gene therapy treatment for osteoarthritis, was approved by Korea’s health authorities in July 2017. Hainan Province, an island off China’s southwest coast, is China’s center for medical tourism. The area can dispense drugs and use medical devices without the approval of Chinadrug regulators. As part of the deal, China Life Medical will conduct clinical tests of Invossa-K for mainland China approval.

Source: China Biotoday

Biotechnology Genomics Healthcare Services Life Science Medical Device Pharmaceutical